BioWorld Asia

Jan. 22, 2003

View Archived Issues

Future Drugs Could Disrupt Protein Biosynthesis In Cancer

Procognia Closes $4M Round, Acquires Sense Proteomic Ltd.

Cyclacel Starts Phase II Trials Of Small-Molecule CDK Inhibitor

EU Leaders Support Worldwide Ban On Reproductive Cloning

ReNeuron Shares Drop On Failed Phase II Trials Of Lead Product

Second Complication Arises In French Gene Therapy Trial

Xenova Paying $1M For Rights To Two Addiction Vaccines

Adebag Planning Biotechnology Cluster In Southeastern France

Cerep Collaborates With Pfizer On BioPrint Database, Software

Other News To Note

Biolipox Raises EUR21M To Fund Drug Discovery, Development

Swedish drug discovery and development firm Biolipox AB raised €21 million in a second-round financing led by the Paris office of Apax Partners. (BioWorld International) Read More

U.S. Officials Step Up Threats Over European Ban On GM Crops

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Korsana boosts Alzheimer’s work with reverse merger, $380M financing

BioWorld Science

Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...